The Influence of H2 blocker on the Antiplatelet Effect of Clopidogrel
Not Applicable
- Conditions
- ischemic heart disease
- Registration Number
- JPRN-UMIN000003407
- Lead Sponsor
- Department of Cardiovascular Medicine, Kyoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) contraindicative patients of aspirin and clopidogrel, 2) patients with warfarin, 3) patients with thrombolytic therapy within 2 weeks, and 4) patients taking ticlopidine, cilostazole or dipyridamole within 1 month 5)chronical renal failure(Cre>1.5)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Maximal Platelet Aggregation Rate after intake of H2 blocker
- Secondary Outcome Measures
Name Time Method